Clinical trial NCT01325454: Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions
Official title: Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pleural Effusion
Keywords: Pleural effusion
angiogenic cytokine
fibrinolytic activity
Lead sponsor: Taipei Medical University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2011-03-29
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included.

Brief summary: Angiogenesis is a key process in the formation of exudative pleural effusions. Fluid loculation is common in parapneumonic effusion and is associated with depressed pleural fibrinolytic activity and poor clinical outcome. However, the relationship between angiogenic cytokines and fibrinolytic activity in the pleural space remains unclear. The researchers's hypothesis is that the levels of angiogenic cytokines were increased and associated with decreased fibrinolytic activity in parapneumonic effusions which may contribute to fibrin deposition and fluid loculation in the pleural space.

Detailed description: Formation of parapneumonic effusions (PPE) involves increased pleural vascular permeability induced by the contiguous pneumonia. It has been demonstrated that exposure of pleural mesothelial cells to bacteria or lipopolysaccharide (LPS) leads to increased release of angiogenic factors, including vascular endothelial growth factor (VEGF) and interleukin (IL)-8, which induce vascular hyperpermeability, fluid exudation, and neutrophil influx into the pleural space, and may play a pivotal role in development of PPE. With persistent inflammation and angiogenesis, amplified vascular and mesothelial permeability leads to increased plasma extravasation, activation of the coagulation cascade, and repression of fibrinolytic activity within the pleural cavity, which contribute to the development of a ''complicated'' PPE, manifested with fibrin deposition and pleural fluid loculation. Fibrin turnover in the pleural cavity is greatly affected by fibrinolytic activity mediated by plasmin, which is regulated mainly by the equilibrium between plasminogen activators (PAs) and plasminogen activator inhibitors (PAIs).VEGF induces vascular hyperpermeability and may facilitate the genesis of fibrin gel in PPE. Previous studies reported that VEGF plays a role in the modulation of tPA and PAI-1, and that anti-VEGF antibody attenuates pleurodesis induced by transforming growth factor-β2. These findings suggest that VEGF may be involved in the regulation of fibrin turnover, fluid loculation and tissue fibrosis in the pleural space. Enhanced procoagulant and depressed fibrinolytic activities have been observed in PPE. However, the relationship between angiogenic cytokines and fibrinolytic activity in PPE remains unclear.

Eligibility criteria: Inclusion Criteria:

* Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).

Exclusion Criteria:

* History of chest trauma or invasive procedures directed into the pleural cavity; bleeding disorder or anticoagulant therapy
* Use of streptokinase in the previous 2 years; and likely survival less than 6 months.

Primary outcomes:
measure: Response to treatment including improvement in vital signs and chest radiography
timeFrame: 5 days after treatment within admission
Secondary outcomes:
measure: Chest radiography and pulmonary function testing with spirometry.
timeFrame: At discharge, and at 6 months
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Division of Pulmonary Medicine, Taipei Medical University Hospital
Study officials:
affiliation: Division of Pulmonary Medicine, Taipei Medical University, Taipei, Taiwan
name: Chi-Li Chung, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: